Podcasts about pediatric oncology

Dr Bill Nelson talks with Dr Christine Pratilas, the new Director of Pediatric Oncology at the Johns Hopkins Kimmel Cancer Center, about the care of children with sarcoma and the importance of research funding in discovering new treatments for childhood cancers.

Adolescents and young adults (AYAs) face poorer cancer outcomes and experiences compared with younger and older patients, and they historically have been lost between pediatric and adult models of oncology care. The Association of Cancer Care Centers (ACCC) is committed to providing up-to-date guidance on treating AYA patients with cancer to improve their outcomes. In this episode of CANCER BUZZ, a team from the University of North Carolina (UNC) AYA Oncology Program shares how it's meeting the unique needs of this patient population by providing developmentally appropriate cancer care through a multidisciplinary approach, including clinical trial access and interactive infusion space; sharing resources where AYAs need additional support; and developing education about fertility and the short- and long-term impacts of cancer. “We talk about things like sleep, mental health, diet, exercise, knowing all of those aspects of life have been impacted by cancer and its treatment, and in order to have the best quality of life and best outcomes, we need to pay attention to all of those aspects of an AYA survivors' life.” – Andrew Smitherman, MD, MS “We know that AYAs are one of the most underinsured or uninsured populations in the United States, and so that means often they are at least initially facing these diagnoses without any insurance at all to help defray the costs.” – Jacob Stein, MD, MPH “My approach [for talking about long term effects] is that patients want to be able to have the opportunity to receive information.” – Alison Manikowski, PsyD Read the full article here. Guests Andrew Smitherman, MD, MSc AYA Medical Director Pediatric Oncologist UNC Adolescent and Young Adult Cancer Program Lineberger Comprehensive Cancer CenterChapel Hill, NC   Jacob Stein, MD, MPH AYA Oncology Liaison Medical Oncologist UNC Adolescent and Young Adult Cancer Program Lineberger Comprehensive Cancer CenterChapel Hill, NC   Alison Manikowski, PsyDAYA Program Pediatric Psychologist UNC Adolescent and Young Adult Cancer Program Lineberger Comprehensive Cancer CenterChapel Hill, NC Resources:  UNC AYA Cancer Program ACCC AYA Resources

Kenny and Mike review, spot faith elements, and interview Natalie Dormer who stars as pioneering pediatric oncologist Audrey Evans in the biopic film Audrey's Children. Audrey Evans became Director of the Pediatric Oncology department at the renowned Children's Hospital of Philidelphia (CHOP) in 1969, and was a trailblazer as both the first department chief and one who introduced new methods for tracking and treating pediatric cancer.  As a hospital with a strong national reputation, parents brought their children from all over the region and country. Out of concern for the parents who were often forced to sleep on the floor of the Oncology ward, Audrey purchased a home that could be used to offer free housing for parents.  This home and program grew into the Ronald McDonald House Charities.  Clancy Brown Co-stars as Dr. C. Everett Koop who served as chief of pediatric surgery at CHOP and was responsible for recriting Dr. Evans. Koop who would later serve as U.S. Surgeon General supported Dr. Evans in the early years of her career including her development of the Evans Staging System which charted Neuroblastoma disease progression and allowed for the most effective treatments.        Faith Spotted: Faith grounded Audrey and inspired her to confront successfully the challenges and roadblocks she encountered as a trailblazing female department chair with new diagnostic and treament procedures.  The film speaks to the purpose and power of calling and the transformative impact it can have in the lives of others. Audrey's calling was to serve children and families in the midst the most difficult circumstances. The film lifts up the importance of children echoing the teaching of Jesus to remove any barriers to children fully living into the life of their community and deserving of the attention of God. Audrey's story reflects the call to live one's life to the fullest, utilizing the gifts and talents God has given. Life is not to be wasted.          

"Audrey's Children" had its world premiere at the 2024 Tribeca Festival, where it received positive reviews for its depiction of healthcare pioneer and Ronald McDonald House Charities co-founder Dr. Audrey Evans (played by Natalie Dormer), who served as Chief of Pediatric Oncology at the Children's Hospital of Philadelphia. Director Ami Canaan Mann was kind enough to spend some time speaking with us about her work on the film, which you can listen to below. Please be sure to check out the film, which is now playing in theaters. Thank you, and enjoy! Check out more on NextBestPicture.com Please subscribe on... Apple Podcasts - https://itunes.apple.com/us/podcast/negs-best-film-podcast/id1087678387?mt=2 Spotify - https://open.spotify.com/show/7IMIzpYehTqeUa1d9EC4jT YouTube - https://www.youtube.com/channel/UCWA7KiotcWmHiYYy6wJqwOw And be sure to help support us on Patreon for as little as $1 a month at https://www.patreon.com/NextBestPicture and listen to this podcast ad-free Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, we're joined by Dr. Daniel Indelicato and Dr. Rohan Deraniyagala, two distinguished experts whose work is transforming the landscape of pediatric oncology. With decades of combined experience and groundbreaking research, Danny and Rohan offer invaluable insights into the world of proton therapy. Listen as they unpack the distinct advantages of proton therapy, shedding light on why this method is especially beneficial for children by minimizing harmful side effects and enhancing quality of life post-treatment.The views expressed in this podcast are those of the interviewees. By listening to this, you agree not to use this podcast as medical advice to treat any medical condition in either yourself or others, including but not limited to patients that you are treating.  Consult your own physician for any medical issues that you may be having.  This entire disclaimer also applies to any guests or contributors to the podcast.  Under no circumstances shall Ion Beam Applications SA (IBA), any guests or contributors to the podcast, or any employees, associates, or affiliates of IBA be responsible for damages arising from use of the podcast.

Dr Dagmara Beine is revolutionizing the Pediatric Cancer World! She holds a PhD in Integrative Medicine, and has over a decade of experience in Emergency Medicine, as well as being the CEO and practitioner at her Wisconsin-based integrative health clinic, Zuzas Way Integrative Care. Dagmara a pediactric oncology specialist who has seen many cases of Radical Remission during her years in practice. Visit Zuzas Way Integrative Care at zuzasway.com Connect with Dr. Beine here on Instagram. Click here to purchase her book, "Parents Guide to Childhood Cancer". _____________________ To learn more about the 10 Radical Remission Healing Factors, connect with a certified RR coach or join a virtual or in-person workshop visit www.radicalremission.com. To watch Episode 1 of the Radical Remission Docuseries for free, visit our YouTube channel here.  To purchase the full 10-episode Radical Remission Docuseries visit Hay House Online Learning. To learn more about Radical Remission health coaching with Liz or Karla, Click Here Follow us on Social Media: Facebook  Instagram  YouTube ______________________________ Many Thanks to Datar Genetics for sponsoring this episode of the podcast! Datar Cancer Genetics is a global leader in developing blood-based oncology panels that can detect cancer, identify treatment options for improved outcomes, and assess remission status. With facilities in Europe, Asia, and the United States, Datar Cancer Genetics believes that through relentless research, bold initiatives, sustained commitment, and an unapologetic determination to succeed against cancer, innovations will continue to be made to help defeat the disease. Stop undergoing unnecessary invasive procedures and having your cancer treated through a trial and error approach. Through a simple blood draw, Datar Cancer Genetic's award winning platforms can accurately diagnose cancer, develop a treatment plan tailored to your cancer's individual composition, and detect a cancer recurrence prior to imaging. To learn more about their tests, please contact Chad their Director of Business Development via his email - ChadB@DatarPGX.com. Visit Datar's website at https://datarpgx.com

Send us a textFor children and adolescents with cancer, exercise is a proven way to improve quality of life, cancer-related fatigue, and physical strength. Yet, many young patients struggle to stay active, especially during hospitalizations. Enter Virtual Reality (VR), an innovative tool that's bridging the gap between exercise recommendations and real-world challenges.In this episode, I sit down with experts Mary Hunter, PT, & Dr. Stephanie Hunter, PT, from Stanford Children's Hospital to discuss how VR is reshaping pediatric oncology rehab. You'll hear about VR's unique benefits—like pain reduction, improved patient engagement, and enhanced endurance—and unpack the latest research, case studies, and practical tips for incorporating VR into your patient care. If you're curious about how technology can elevate your practice and your patients' experiences, this episode is for you!

Listen to November's Pediapod episode: What's hot in Pediatric Oncology? with Jeffrey Dome Hosted on Acast. See acast.com/privacy for more information.

This time on Code WACK! Imagine learning that your baby girl has a brain tumor that's causing seizures and disrupting her development, and your health insurance company is denying coverage for the treatment her pediatric oncologist says she needs to survive and thrive? What would you do? Where did one mother turn when repeated health insurance denials delayed time-sensitive treatment to shrink her baby's tumor?  To find out, we spoke to Dr. Eunice Stallman, a psychiatrist in Idaho and clinical faculty at the University of Washington School of Medicine and the University of Washington Boise Psychiatry Residency Program. Her daughter Zoey is two years old now and still undergoing medical treatment. This is the first episode in a two-part series. Check out the Transcript and Show Notes for more!  

Editor's Summary by Linda Brubaker, MD, and Preeti Malani, MD, MSJ, Deputy Editors of JAMA, the Journal of the American Medical Association, for articles published from November 9-15, 2024.

Join Dr. Clancy and his guests, Drs. Elizabeth Amelon, David Dickens, and Rachel Kinn as they discuss guidance for clinicians in using opiods for end of life pediatric patients.  CME Credit Available:  https://uiowa.cloud-cme.com/course/courseoverview?P=0&EID=71737  Host: Gerard Clancy, MD Senior Associate Dean for External Affairs Professor of Psychiatry and Emergency Medicine University of Iowa Carver College of Medicine Guests: Elizabeth Amelon, MD Pediatric Clinical Pharmacy Manager University of Iowa Health Care David Dickens, MD Clinical Professor of Pediatrics - Hematology/Oncology University of Iowa Dance Marathon Endowed Chair in Pediatric Oncology, Clinical and Tranlational Research Clinical Director of Pediatric Oncology Services University of Iowa Health Care Rachel Kinn, MD Clinical Pharmacy Specialist University of Iowa Health Care Financial Disclosures:  Dr. Gerard Clancy, his guests and the members of the planning committee for Rounding@IOWA have no relevant financial relationships to disclose. Nurse: The University of Iowa Roy J. and Lucille A. Carver College of Medicine designates this activity for a maximum of 0.75 ANCC contact hours. Pharmacist: The University of Iowa Roy J. and Lucille A. Carver College of Medicine designates this knowledge-based activity for a maximum of 0.75 ACPE contact hours. Credit will be uploaded to the NABP CPE Monitor within 60 days after the activity completion. Pharmacists must provide their NABP ID and DOB (MMDD) to receive credit.  UAN: JA0000310-0000-24-087-H01-P Physician: The University of Iowa Roy J. and Lucille A. Carver College of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other Health Care Providers: A certificate of participation will be available after successful completion of the course. (It is the responsibility of licensees to determine if this continuing education activity meets the requirements of their professional licensure board.)  

Regina Demlová leads the CREATIC Center of Excellence, established in 2023 at the Faculty of Medicine, focused on rare undiagnosed diseases, high-risk pediatric tumors, and ATMP treatments for adult cancer patients. Jaroslav Štěrba heads the Department of Pediatric Oncology at the Faculty of Medicine and University Hospital Brno, serves as vice-dean, and is a member of the European Medicines Agency's Paediatric Committee. CZECRIN, the Czech Republic's key infrastructure for academic clinical research, connects national institutions to international clinical research through the European network ECRIN-ERIC.

For decades, academic clinical trials consortia have collaborated to optimize outcomes for childhood cancers through evaluating incremental improvements in conventional multi modality treatment regimes. There are now increasing opportunities to partner with industry to test new medicines in academic-sponsored trials, but these collaborative studies rarely contribute to marketing authorizations. Under the auspices of the multistakeholder platform ACCELERATE, a working group of representatives was convened from clinical academia, the pharmaceutical industry, the European Medicines Agency, US Food and Drug Administration, and patient advocacy to explore why this is the case and to seek solutions to enable academic-sponsored trials to directly contribute to the licensing of new medicines. This presentation summarizes the group's findings and provides an industry perspective on how to move forward.Dr. Barry is a board-certified pediatrician and pediatric hematologist/oncologist with over 15 years of experience in drug development. Prior to joining Day One in 2021, she was the Global Clinical Lead for Pediatric Oncology at Pfizer, as well as Head of Pfizer's Pediatric Oncology Leadership Team where she oversaw more than 10 pediatric oncology clinical programs. She has also held previous roles at Genzyme and Millenium/Takeda focused on the development of oncology therapeutics in adults. Dr. Barry serves on the Industry Advisory Council for CureSearch and is a member of the ACCELERATE Platform Steering Committee. She is also a co-chair of the Children's Oncology Group Industry Relations Council. Dr. Barry is a graduate of the pediatric hematology/oncology fellowship program at the Dana Farber Cancer Institute and Children's Hospital Boston, and the pediatric residency program at Tufts. She received her M.D. at Yale University School of Medicine and also obtained a Masters in Medical Science degree from Harvard Medical School.

“These evidence-based standards provide a great framework for best practice in cancer care and the 2016 publication is extensively referenced. However, patient care mistakes and medication errors still happen. So, it's imperative that we review the current literature and look for new evidence that's been published,” ONS member MiKaela Olsen, DNP, APRN-CNS, AOCNS®, FAAN, clinical program director of oncology at Johns Hopkins Hospital and Johns Hopkins Health System told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the new Antineoplastic Therapy Administration Safety Standards for Adult and Pediatric Oncology from ASCO and ONS. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at myoutcomes.ons.org by August 16, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to increasing safety of antineoplastic medication administration. Episode Notes  Complete this evaluation for free NCPD. Oncology Nursing Podcast™ episodes: More episodes about antineoplastic administration Episode 209: Updates in Chemo PPE and Safe Handling Episode 142: The How-To of Home Infusions ONS Voice articles: Are You Following the Latest Chemo Safety Recommendations? Hazardous Drug Surface Contamination Prevails, Despite More Diligent PPE Respect Patients' Religious Hair Wraps or Coverings When Taking Accurate Height and Weight Measurements ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Oncology Nursing: Scope and Standards of Practice Safe Handling of Hazardous Drugs (fourth edition) ONS courses: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ Safe Handling Basics Antineoplastic Therapy Administration Safety Standards for Adult and Pediatric Oncology: ASCO-ONS Standards Oncology Nursing Forum article: ASCO/ONS Antineoplastic Therapy Administration Safety Standards ONS Learning Library: Safe Handling of Hazardous Drugs To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an Oncology Nursing Podcast™ Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “The target population for these standards are, first, our patients—adult and pediatric patients with cancer who are receiving antineoplastic therapy—but as well as those who care for patients with cancer. And we're not distinguishing between the healthcare worker, the caregiver, all people who care for patients with cancer, including those practitioners or healthcare workers that are not in a traditional oncology setting.” TS 3:25 “The audience is, first of all, oncology clinicians. We spent a lot of time on this panel writing the definition, so it was very clear who people were as we use terminology in the standards. So, an oncology clinician, when we refer to that in the standards, that's a licensed nurse, like a nurse or pharmacist, a licensed clinician, or it could be a non-licensed clinician like a patient care assistant or tech. So, we refer to people as clinicians that are licensed or unlicensed.” TS 4:14 “We need to define all types of therapy for cancer, and chemo is one type of treatment modality. The explosion of new therapies that include cellular therapies such as CAR T and other exciting emerging treatment options are not our traditional chemotherapy. And so the term antineoplastic was agreed upon for all these therapies to treat cancer. That definition in the standards is, and I quote, ‘All antineoplastic agents used to treat cancer regardless of the route.' And that's important because the previous guidelines were not as inclusive about that.” TS 6:58 “Another high-level change was the new language about the location of administration to include new healthcare settings. We know that antineoplastic medications are given in a variety of settings, not just your typical inpatient or ambulatory oncology infusion center anymore. We've got health plans that are increasingly developing strategies to direct patients to more convenient and less costly sites of service, such as the physician's office or home infusion, unregulated sites, and more care is being given in these settings. So, it's really important that we adapt the standards to make sure those patients treated in the home or in a freestanding center are given the same opportunity for safety and quality.” TS 8:39 “The other thing in Domain 1 that I think is crucial for nurses to understand, because it's a big change, and we made this change based on the literature, looking at patient safety events related to inaccurate weight and height measurements. Domain 1 has a standard 1.7 that says weight and height are measured and documented in the medical record in metric units only. And I see that a lot when I'm going around the country. People still have their scales and pounds and their height in inches, and we've got to change that. We shouldn't be converting things. Both the measurement and the documentation are verified by two individuals, one of whom is a licensed clinician. Prior to preparation and administration of a newly prescribed antineoplastic treatment plan.” TS 13:32 “That third verification is an independent safety check and, in my opinion, should be done in a quiet place where you can go through and do the safety checks that are listed in the standards quietly and thoughtfully, without being in the presence of the patient or caregiver. Those are done in an attempt to do some preliminary safety checks to make sure that when I go in the room to do my safety checks—we often call those bedside safety checks—that if I have an error before that with a dose or something, I've caught that before I get to the patient's side.” TS 20:52

Kelley Bernard was diagnosed with Acute Lymphoblastic Leukemia when she was 14 years old and has now been cancer free for the past 16 years. Because of the treatment that she received from the nurses at Boston Children's Hospital , Kelley decided that she wanted to become a Pediatric Oncology Nurse which became her career path after graduating from St.Anselm's College with a Nursing Degree. Kelley has also participated 3 times in both the Boston Marathon Jimmy Fund Walk and the Pan Mass Challenge and is currently training for her upcoming boxing match hosted by the Non-Profit Haymakers For Hope. 

Various survivorship guidelines for pediatric patients have been established, but “such guidelines do not exist in the adult world,” says Smita Bhatia, MD, MPH, director of the Institute for Cancer Outcomes and Survivorship and the Gay and Bew White Endowed Professor in Pediatric Oncology at the University of Alabama at Birmingham. With the number of adult cancer survivors rapidly rising, the time is now for major oncology societies to help create long-term health recommendations, she tells Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles. Dr. Bhatia and Dr. Figlin discuss the critical need to explore how recent advances in cancer care, such as targeted treatments and immunotherapies, may affect the future health of survivors. “If we don't start by constructing large cohorts and following them long term, we will have lost this opportunity that exists right now,” she explains. Dr. Bhatia is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of the manuscript discussed. Dr. Figlin reported various financial relationships.

Mecklin Ragan is currently a General Surgery Resident in Fairfax , Virginia who hopes to become a Pediatric Oncology surgeon . She was also the older sister by 18 months of her brother James who was diagnosed with Osteosarcoma in 2006 at the age of 13. Mecklin tells the story of James who went through a 7 1/2 year protocol which unfortunately ended with his passing from Rice University during his sophomore year. Mecklin is the co-founder of the Triumph Over Kids Cancer Foundation, which is doing a great deal of work to help Pediatric Cancer patients and their families.

Amanda Curry is a trauma-informed Doctor of Physical Therapy, a Certified Oncology Specialist, a Training Camp for the Soul™ Master Facilitator, a Breathwork Facilitator, and an Inner Child and Reparenting Coach. Unafraid of big emotions and deep work, she is a solid space holder for the most tender parts of those she works with. Helping parents (moms in particular) is her calling. She teaches them how to be with their own emotions so they can be present parents for their kids, eliminating the tendency toward reactivity that is present when overwhelm takes hold. Through somatic tools like breathwork, use of felt sense, and inner child reparenting techniques, she guides others in uncovering the root beliefs that are keeping people stuck in overwhelm and frustration.  https://www.instagram.com/thesomaticdpt/

In 2008, Dr. Susannah Koontz left her role as a Clinical Pharmacy Specialist at MD Anderson and started her own Oncology Consulting business called Koontz Oncology Consulting, which she has been at since 2008. Dr. Koontz will first discuss some of the improvements and standards that she initiated at MD Anderson which still are in place today, and then talk about her consulting company and the different interest groups that she deals with and the different facets of Pediatric Oncology that are of prime importance, as she tries to help these kids and the treatment that they receive for their own cancer battles. 

Dr. Bradley Hunter, MD, MPH and Ms. Amy Evers, BSN, RN, OCN, MBA join us on the latest episode of the ASCO Guidelines Podcast to share key points and insights on the updated ASCO-ONS antineoplastic therapy administration safety standards for adult and pediatric oncology standards. They highlight key updates across the four standards domains: (1) creating a safe environment, (2) patient consent and patient education, (3) ordering, preparing, dispensing, and administering oral and parenteral antineoplastic therapies in a health care facility, organization, or in the home, and (4) monitoring during and after antineoplastic therapy is administered, including adherence, toxicity, and complications. They also comment on the importance of these standards to provide a framework for optimal safe and effective care for all patients. Read the standards, “Antineoplastic Therapy Administration Safety Standards for Adult and Pediatric Oncology: ASCO-ONS Standards” at www.asco.org/standards. TRANSCRIPT These standards, clinical tools, and resources are available at www.asco.org/standards. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the JCO Oncology Practice, https://ascopubs.org/doi/10.1200/OP.24.00216 Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Bradley Hunter from Intermountain Health and Amy Evers from the University of Pennsylvania, authors on “Antineoplastic Therapy Administration Safety Standards for Adult and Pediatric Oncology: American Society of Clinical Oncology – Oncology Nursing Society Standards.” Thank you both for being here. Dr. Bradley Hunter: Yeah, thanks. Good to be with you. Amy Evers: Thank you. Brittany Harvey: Now, before we discuss these standards, I'd like to note that ASCO takes great care in the development of its guidance products and ensuring that the ASCO Conflict of Interest Policy is followed for all standards. The disclosures of potential conflicts of interest for the expert panel are available online with the publication of the standards in the JCO Oncology Practice, which is linked in the show notes.  So then to start us off, Dr. Hunter, what prompted an update to the ASCO-ONS standards? And what is the scope of this update? Dr. Bradley Hunter: The last guidelines were published in 2016. And just thinking about in the world of oncology, so much has changed since that time. There are a lot of therapies that have become commonplace now that were really not used too much before, including oral genomically determined targeted therapies, immunomodulatory agents, CAR T cell therapy, bispecific antibodies, etc. So there's really been a need to just talk about how do we navigate those therapies and how do we create systems of care in which they are delivered safely. Additionally, the sites of care have changed. I think all of us, eight years ago, wouldn't have imagined a global pandemic, and how that would have changed the way that we needed to deliver oncology care. So there's been a huge influx of telehealth, including tele-oncology centers, where the oncologist and the patient may never even meet face to face, but just by video. And so it relies on a team approach for that sort of an outreach setting. Intermountain Health spans seven states, there are so many sites like this that we have and I know that we are not unique. This is an issue and a global thing now. Additionally, patients are even getting chemo in their own homes, so that has changed and we need to figure out how to address that so that everyone could be able to have that site of care so they can get there and they can get their therapy in a safe manner.  So, these varied care settings present a challenge to us as oncology providers to ensure that a standard of quality of care is maintained, and that the therapies can be given to patients no matter where they live and that we maximize benefit while minimizing risk to the patient. So I mean, just thinking where we are now, I can't imagine where we're going to be eight years from now or the next time these guidelines are updated. Brittany Harvey: Absolutely. Thank you for setting the stage and the impetus for this update. It sounds like a lot has changed in the last few years to impact these standards.  So then I'd like to review the key points of the standards and the key updates for our listeners. There are four domains of standards. Starting with domain one, Amy, what are the key points of the standards for creating a safe environment for all routes of antineoplastic therapy? Amy Evers: So domain one is all about who can write chemotherapy orders, who can prepare chemotherapy and then who can administer that chemotherapy and then what their competencies are both initial and then ongoing. So looking at the existing standards, we did end up making a few updates mainly on how providers discuss and document pregnancy status and fertility preservation with patients. And I think this is really timely given that we're seeing a big uptick in younger patients that are being diagnosed with cancers that were typically considered “old person diseases”. And I think we can and we should do better in ensuring that patients who want to preserve their ability to have a family one day can do so before they start treatment.  The update also included the addition of an assessment for social determinants of health, calling out financial and logistical constraints that patients may face as part of their cancer journey, which I think is extremely important making sure that we have equitable access to care regardless of a patient's background, their financial status, everybody's receiving the highest quality of care they can in their community.  And the last change that we made was to highlight an accurate measurement of height and weight using metric units, which is important when we're calculating the doses of drugs for some of these very high risk medications.  Brittany Harvey: Excellent. Thank you for reviewing those important points for our listeners.  So following those standards, for domain two, Dr. Hunter, what are the key standards for patient consent and patient education? Dr. Bradley Hunter: In domain two, we're really seeking to figure out what policies around treatment planning, patient consent and patient's education are shown to result in fewer medical errors and reduce preventable harm? But one of the big things we've found is having a really detailed understanding of exactly what a patient is taking in terms of medications, including over the counters and supplements and herbal remedies, really helps reduce medical errors. You know, some of the research and literature we came across suggest that upwards of 80% of the time when you see a patient's medication there are discrepancies between what's on that list and what patients are actually taking. So being able to sit down as part of a consent discussion and ongoing care and talk about everything that a patient's taking is really important.  My background, I am a bone marrow transplant, stem cell transplant and cellular therapist. Just this last weekend I was on the inpatient service and a patient had brought in food from home which we completely are supportive of. The patient brought in a bunch of superfood shakes that she had bought at Costco and then some CBD tea and she asked us if it was okay if she could take those. And as we reviewed them and what was in all of those shakes and then what was in the CBD tea, there were major interactions between those supplements or those herbal remedies, and then what was in the medications we were giving in the hospital, so it was important. And she told us - it wasn't like I sat down and and was the shining example here, but it was helpful that we were able to take her global picture of what she was taking from a medication standpoint and be able to make sure that we were treating her in a safe manner and making sure that we weren't inadvertently causing harm.  So, those are some of the things that we talked about. So, at every patient visit, and especially the first time you meet a patient you're going to start therapy to be able to go over all of the different substances that patients are taking to make sure that they're safe.  Brittany Harvey: Thank you so much for reviewing those key standards and key updates and that example of how important it is to review all of medications and herbal supplements that patients are taking to ensure safe care for our patients.  So then following that, Amy, for domain three, what are the key points regarding ordering, preparing, dispensing and administering oral and parenteral antineoplastic therapy in a healthcare facility organization or in the home? Amy Evers: So, domain three, actually, it was the domain that had probably the biggest discussion and fruitful debate between the panel members, but I think that we had some really great discussions and I think we had brought some really good changes and updates to the standards here. So domain three is where all of the verification standards live. So this is for practices who would either have been through the QOPI certification process or have been QOPI certified. This is where the surveyor actually will observe in real time how the clinical orders are reviewed by staff, how the drugs are prepared by pharmacy, and then how the drugs are checked one final time at the chair side or bedside immediately prior to administration.  So as I mentioned earlier, antineoplastic therapies are being given more frequently in the home or in settings where there may not be two clinical staff members present. In this post-COVID world, we're finding patients can be treated safely in the home, but the standards didn't really reflect kind of these changes in where patients are receiving treatment. And often, more and more practices are relying on technology to supplement the verification process both either in the pharmacy setting where there may be a centralized pharmacist verifying the drug mixing process for multiple sites, or in the actual home setting where a nurse can connect virtually with another clinician to verify a drug immediately or administration. So the standards were updated to include these workflows. And I think it's becoming more and more commonplace, but how do we do this in a safe and effective way where we're ensuring that all of these same safe handling processes are completed, regardless of where the patient may be seeking treatment?  So previous versions of the standards had three verifications. The first was before the actual preparation of the drug that someone other than the provider who wrote the order is verifying the order for all of the correct elements. The second verification is what usually happens in the pharmacy, upon preparation, what's being checked by the pharmacist or pharmacy technician who's preparing the drug. And then a third verification is done at, generally, the chair side where they're doing one final check of the orders to the drug to the patient.  So with this update, we actually broke out that third verification into a fourth verification. So the third verification is that check with the drug in the order by the administering and then a second verifier. And then the fourth verification is actually the one where the patient's involved in the verification. So there are two clinicians making that final double check with the patient immediately upon preparation, which I think is important and is reflective of this change that we're seeing more drugs being administered in the home setting. The chair side or bedside final verification was also expanded to include a visual inspection of the administration tubing, this is sometimes referred to as tracing the lines, which ensures that the drug is being accurately infused, that there aren't any loose connections, that the clamps are open etc. And I think this is something that most nurses do in their normal clinical practice, but I think adding this as an actual check in the verification process, is really important. And I know personally, I was really happy to see this added in as a formal check. Dr. Bradley Hunter: Yes, thanks, Amy. One other new standard within domain three is regarding immunomodulatory or immune effector cell therapies that have the risk of cytokine release syndrome and how we build a framework to try to mitigate those toxicities. We really wanted to try to make a set of standards that would apply whether or not you're at a coronary care center, like Penn or whether you were at a center, like within Intermountain Health, it's a small rural outreach center that you're trying to be able to get patients to care. So really, the main thing within dealing with therapies that have the risk of cytokine release syndrome is really just building a framework that there's a management policy that's present from the institution, and that it's up to date, it's following what we know will work for these therapies in order to mitigate their toxicity, and then also making sure that adequate antidote therapy, whether for example, for cytokine release syndrome, it could be tocilizumab or anakinra or other therapies, and that order sets are present to be able to follow along with the policy guidelines to guide clinicians wherever they are practicing to help mitigate cytokine release syndrome, neurologic toxicity, ICANS, or other sorts of therapies that are associated with these novel agents.  Brittany Harvey: So for or the last domain, domain four, what are the key points for monitoring during and after antineoplastic therapy is administered, including adherence, toxicity, and complications? Amy Evers: So domain four is pretty straightforward. It discusses the importance of assessing adherence and toxicities related to antineoplastic treatments. There wasn't a whole lot of updates here. We did include having emerging treatment plans or equipment in the home and the healthcare setting. But what I really think is important and we need to underscore both with patients and clinicians, particularly as we've seen this rise in oral chemotherapy agents, is that a lot of times patients forget that this is the same chemotherapy that they're getting in the infusion suite. They're just taking it in a pill form. And I think patients forget that their adherence is just as important in taking that pill regularly and as prescribed. Financial toxicity is a real problem for most of our patients. Some of these drugs cost hundreds if not thousands of dollars for one treatment plan. As clinicians we've all heard stories of these patients who try to extend their prescription so they'll take a pill every other day instead of daily as prescribed, which really doesn't let the drug do what it's supposed to do. So I think when we talk about adherence, it's not just asking a patient whether they've taken their drug, it's about whether or not oral therapy is even appropriate for that particular patient. Do they have memory problems? Do they have metastatic disease to the brain where they may not be able to follow a complicated oral regimen? Do they have arthritis where opening a pill container is difficult? So having these conversations before a drug is even prescribed and making sure that it's the right route of administration for a patient is just as important as ensuring that they're maintaining their adherence to that drug.  And oftentimes, the toxicities of these oral drugs are worse than what's actually being administered in some of the infusion clinics, and so making sure that we're checking in on these patients regularly to ensure that they're not having any toxicities that aren't being managed appropriately. Or if there may be toxicities that would require a dose reduction, or perhaps switching to a different drug entirely. So, even though it's a pretty simple and straightforward domain, I think it's really important that we're educating our clinicians and our patients about the importance of adherence.  Dr. Bradley Hunter: I completely agree with what Amy said. She said it so well. I just want to echo back a couple of things that she said. Historically, we use the word non-compliant, which I think kind of sounds terrible to describe the patient's adherence to medication. I think part of this domain is recognizing that there is an entire environment that has to do with the patient that influences the way they're able to take their medication whether that's financial toxicity; we were talking to two people in our clinic who are professional financial toxicologists, and their entire job description is to help people get drugs for less so that they can actually take the side effects. If a patient feels terrible at that time, they're not going to take it. So, understanding these barriers and really understanding the patient's entire picture, when you're figuring out how is the treatment plan going to match up with their reality, I think is super important.  When it comes to site of care, we just want to make sure also that whether you're getting chemo at home or you're getting chemo in the clinic down the street, or in a coronary care center, that there is a policy in place to respond to an emergency, but also the equipment available in all of those sites of care that you can respond. And that's another aspect that we wanted to make sure we hit in the domain as there's been so many changes in how patients get care in the last eight years. Brittany Harvey: Absolutely. Recognizing the barriers and factors that impact the ability of an individual to receive the right therapy is crucial. And I want to thank you both for reviewing all of the standards and updates through all four domains.  So then following that, in your view, how will these updated standards impact clinicians? Dr. Bradley Hunter: It's our hope that these standards will guide the development of treatment infrastructure and help clinicians avoid error prone environments. We hope they're going to guide training efforts and that they will help clinicians ensure that they have relevant and accurate information about their patients and are able to respond appropriately when emergencies or even urgencies arise. Because of COVID, there's been such high staff turnover. And in the midst of all of this change, it's difficult to maintain a culture of safety when you've lost a lot of institutional knowledge of how to deal with that. And so, really trying to help bring people together again to have an infrastructure in place that makes training as seamless as possible and deal with the historical high staff turnover we've had.  So we're again, hopeful that we're helping to create a framework that cancer centers, treatment centers can use, whether they are a coronary care center in a large academic space, or whether they're in a rural tele-oncology space to be able to use the standards to create a space and a place and experience for cancer patients in which they're kept safe and we're maximizing the benefit of their chemotherapy, their antineoplastic agents, and also minimizing the risk just to optimize benefits for the patient.  Brittany Harvey: Definitely. Those are key points to provide a framework for clinicians.  So then along those same lines, finally, what does this update mean for patients receiving antineoplastic therapy?  Amy Evers: So while these standards are not necessarily patient facing, what I hope that this update will do, or actually not do, is that a patient shouldn't recognize any change in how they are cared for, regardless of what setting that they're receiving treatment. So whether it's at home, whether it's an ambulatory infusion center or in the hospital, they're still going to receive that same level of high quality care while they're receiving treatment. And I think that that's the most important thing that they should take away from this. Brittany Harvey: Absolutely.  So I want to thank you both so much for all of your work on these standards to ensure patients receive optimal safe and effective care. And I want to thank you both so much for your time today.  Amy Evers: Thank you so much.   Dr. Bradley Hunter: Yeah, thank you. It's really great to talk about this stuff.  Brittany Harvey: And thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the complete standards go to www.asco.org/standards. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.  The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.      

Today's Raise the Line guest has a simple but powerful message for medical providers, born of a mother's heartbreak. “It's going to be rare in your career to meet a zebra but the impact you can have is phenomenal. An early diagnosis could make the difference between life and death for these children,” says Bethan Keall who lost her young daughter Matilda (Tilly) in 2022 to neuroblastoma, a rare cancer most commonly found in children. Because some symptoms of the disease can be easily attributed to other causes, early diagnosis is difficult, particularly if providers are not on the lookout for it. Tilly's diagnosis of an aggressive form of neuroblastoma introduced Bethan and her husband to the unfortunate realities of a lack of funding and coordination in the UK around pediatric oncology. “For childhood cancer you really need as much collaboration among doctors as possible to understand how treatments can get better because there are relatively few cases,” she explains to host Lindsey Smith. In coping with Tilly's tragic death at the age of four, her parents have dedicated themselves to Neuroblastoma UK to support research efforts and have benefitted from the emotional and social support provided by a charity called Jak's Den, founded by the family of a victim of childhood cancer. This is a wrenching, illuminating episode in our Year of the Zebra series offering important insights from a parent's perspective for providers and policymakers alike. Mentioned in this episode: Jak's Den https://www.teamjak.org.uk/Neuroblastoma UK https://www.neuroblastoma.org.uk/ 

Welcome to the first episode of DNA Dialogues! Today is February 29th, 2024. It is a leap year, so today marks an extra special rare disease day.    Rare diseases can impact so many people - from patients themselves, to families, to broader communities. To celebrate rare disease day, we are going to dive into two recent articles from the Journal of Genetic Counseling that showcase the rare disease experience. The following interviews provide insight into the wider impact of rare disease, with a special focus on families.   Segment 1: “Understanding type and quality of relationships between individuals with chromosome 18 syndromes and their siblings”   Dr. Catherine Larson joins us in the first segment to talk about her recent article titled, “Understanding type and quality of relationships between individuals with chromosome 18 syndromes and their siblings”.    Dr. Catherine Larson is a Child and Adolescent Psychiatrist and a sibling to Elizabeth, who has a Chromosome 18 deletion. After earning her undergraduate degree, she worked as a research assistant at the Chromosome 18 Research Center, where she began her research on Sibling relationships. Dr. Larson earned her Medical Degree from the University of Texas School of Medicine at San Antonio. She then went on to complete a General Psychiatry Residency Program, followed by a Fellowship in Child and Adolescent Psychiatry at The University of Texas at Austin, Dell Medical School. As a practicing psychiatrist, she opened her private practice in Austin, Texas, and she also returned to join the research team at the Chromosome 18 Research Center.   Dr. Catherine Larson is double Board Certified by the American Board of Psychiatry and Neurology in General Psychiatry and Child and Adolescent Psychiatry. Dr. Larson earned her Medical Degree from the University of Texas School of Medicine at San Antonio. She then went on to complete a General Psychiatry Residency Program, followed by a Fellowship in Child and Adolescent Psychiatry at The University of Texas at Austin, Dell Medical School. In addition to her private practice, she is currently an Adjunct Assistant Professor at The University of Texas Health School of Medicine at San Antonio.  Segment 2 “Families' experiences accessing care after genomic sequencing in the pediatric cancer context: ‘It's just been a big juggle'”   Authors Sarah Scollon and Blake Vuocolo talk about their recent Journal of Genetic Counseling paper in the pediatric cancer space.    Sarah Scollon is an Assistant Professor in the Department of Pediatrics at Baylor College of Medicine and certified genetic counselor for the Texas Children's Hospital Cancer Genetics and Genomics Program. She has served in dual clinical and research roles across the course of her career. Her research interests engage the overarching themes of (1) adaptation of genetic counseling practice to implement evolving technologies (2) optimization of patient-provider communication and education and (3) equity and inclusion for diverse populations in genetic medicine and research. Ms. Scollon has had a longstanding dedication to the care of children and families affected by cancer. She is an advocate for including genetic counseling into pediatric cancer care. She works to educate others on the role genetics and genomics can play in the care of patients with pediatric cancer and their families both from a clinical and psychosocial standpoint.   Blake Vuocolo is a certified research genetic counselor in the Department of Molecular and Human Genetics at Baylor College of Medicine. She graduated from the Baylor College of Medicine Genetic Counseling Program in 2022, and her thesis work focused on access to follow-up hereditary cancer care in underserved pediatric populations through the KidsCanSeq study. Currently, her work focuses on exome and genome sequencing of medically underserved populations with undiagnosed diseases throughout Texas. Ms. Vuocolo is passionate about finding sustainable ways to improving genomic health equity worldwide. Her interests include exploring access barriers to receiving genomic care in different healthcare contexts and improving genetics education for non-genetics healthcare providers in under resourced regions of the country and beyond.   Stay tuned for the next new episode of DNA Dialogues! In the meantime, listen to all our episodes Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Dialogues”.    For more information about this episode visit dnadialogues.podbean.com, where you can also stream all episodes of the show. Check out the Journal of Genetic Counseling here for articles featured in this episode and others.    Any questions, episode ideas, guest pitches, or comments can be sent into DNADialoguesPodcast@gmail.com.    DNA Dialogues' team includes Jehannine Austin, Naomi Wagner, Khalida Liaquat, Kate Wilson and DNA Today's Kira Dineen. Our logo was designed by Ashlyn Enokian. 

Dr. Andy Livingston is a clinician and researcher in Sarcoma Medical Oncology and holds a joint appointment in Pediatric Oncology, and is Co-director of the MD Anderson Adolescent and Young Adult (AYA) oncology program. His clinical and translational research is focused on developing new treatment strategies for patients with osteosarcoma and other bone sarcomas. Dr. Livingston joins us on OsteoBites to discuss the background and scientific rationale for combining immunotherapy with cabozantinib in teens and young adults with osteosarcoma and provide information about the ongoing TACOS study: Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma.Dr. Livingston is a clinician and researcher in Sarcoma Medical Oncology and holds a joint appointment in Pediatric Oncology at MD Anderson Cancer Center in Houston, Texas. After completing medical school at the University of Texas Medical Branch at Galveston, he went on to residency training at Duke University where he completed a combined residency in internal medicine and pediatrics. Dr. Livingston completed his fellowship training at MD Anderson where he served as the Chief Fellow for Hematology/Oncology Fellowship Program. Dr. Livingston has a particular interest in the care of teens and young adults with cancer and is Co-director of the MD Anderson Adolescent and Young Adult (AYA) oncology program. His clinical and translational research is focused on developing new treatment strategies for patients with osteosarcoma and other bone sarcomas. He received the MIB OutSmarting Osteosarcoma award in 2020 for his work on the immune landscape of osteosarcoma and serves as a member of the MIB Scientific Advisory Board.

Debra L. Friedman, M.D., is a professor of Pediatrics in the Division of Hematology and Oncology at the Monroe Carell Jr. Children's Hospital at Vanderbilt. She is the E. Bronson Ingram Chair of Pediatric Oncology and the leader of the Cancer Control and Prevention Program and directs the Cancer Survivorship programs at the Vanderbilt-Ingram Cancer Center. Dr. Friedman's research interests lie in the long term outcomes for cancer survivors, as well as in the design of novel therapeutic protocols for childhood cancer, designed to decrease adverse long-term effects of therapy. She has leadership roles in Children's Oncology Group (COG) and is an internationally recognized expert in cancer survivorship, participating in projects evaluating best practices and models of care. She is investigating a diverse group of physiologic and psychosocial outcomes among survivors of pediatric cancer, hematopoietic stem cell transplant and medical oncology. Friedman completed her pediatric residency and a joint fellowship in Pediatric Hematology/Oncology and Cancer Epidemiology at the University of Pennsylvania and The Children's Hospital of Philadelphia (CHOP). Prior to coming to Vanderbilt in 2008, she served as the co-director of the Cancer Survivorship Program at CHOP and then, as the founder and director of the Fred Hutchinson Cancer Research Center Survivorship Program. ---- What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

Ep.68 Empowering Children Living with Medical Conditions Through Play ||Mary Jenner RN BSN OCN Helping kids with conditions such as cancer through play is a wonderful way to support them. Playtime is not just fun but a powerful way for these brave kids to feel better emotionally and forget about their illnesses for a while. Giving them toys to play with lets them be creative and strong and have some normal fun, even though they are sick. These toys are like little sparks of happiness in their tough journey and a reminder to them that they are strong and can still be kids and have big dreams, even when things are hard. Join this conversation with Mary Jenner RN, former Pediatric oncology nurse who has dedicated her life to developing medical devices and toys for kids living with cancer.   Mary Jenner wears many hats with passion and purpose. As a loving mother, dedicated nurse, and accomplished author of "The Butterfly Pig," she is also the driving force behind the innovative kid's medical device toys. Mary's mission is to create a world where children can gain confidence and understanding through play, particularly those with medical conditions. Her journey began in the challenging realm of Pediatric Oncology, where she recognized the need for medically inclusive toys. Years later, after nearly eight years of service as a care coordinator and clinic nurse in an adult oncology unit, Mary decided to take her commitment a step further. In April 2023, she bravely left her clinical role to fully devote herself to her thriving business, offering children a brighter, more inclusive future through the power of play.   Tune in!   Key Highlights from the Episode: [00:30] Episode intro and a quick bio of the guest, Mary Jenner [01:44] Meet and greet Mary Jenner and know what her value to the world [05:43] Mary's experiences in hospice and palliative [09:31] Mary's current projects [12:43] Who Mary works with to design the toys from a picture to a real toy [16:14] Success stories of how Mary's toys have helped children [19:09] Other toys available besides the kid's devices [20:07] How you can get Mary's baby products [20:40] Her best medical products [21:46] Who a child life specialist is and their invaluable services [24:16] Golden nuggets and words of wisdom from Mary [26:25] Ending show and calls to action Notable Quotes  ●      Though hospice empowers some people, it can be disempowering to others because they feel as if accepting hospice is like giving up. And that is a tough mindset to change in oncology. [08:00] ●      The way a child learns is through play. [17:56] ●      The understanding of kids is based on them touching things. That is why kids' toys are so important to them. Kids learn and grow when they interact with them. [18:54] Let's Connect Mary Jenner Website: https://thebutterflypig.com/ LinkedIn: https://www.linkedin.com/company/thebutterflypig/ Instagram: https://instagram.com/TheButterflyPig Facebook: https://facebook.com/The-Butterfly-Pig-114229727028293 TikTok: https://www.tiktok.com/@thebutterflypig Mary's Book: https://thebutterflypig.com/book/   Marie's Contact: Marie@HospiceExplained.com www.hospiceexplained.com http://buymeacoffee.com/hospice Marie@HospiceEncounters.com Leave a Voicemail: 206-705-3080                            

In this JCO Article Insights episode, Emily Zabor interviews Dr. Gregory H. Reaman, the Scientific Director of the Childhood Cancer Data Initiative at the National Cancer Institute, on their paper titled  “The Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and Young Adult with Pediatric Cancer”. Dr. Reaman introduces us to the initiative, its goals and structure, and what has already been achieved since its launch. TRANSCRIPT The guest on this podcast episode has no disclosures to declare.  Emily Zabor: Welcome to this JCO Article Insights episode for the August issue of JCO. This is Emily Zabor, JCO's Biostatistics Editorial Fellow. And today I am interviewing Dr. Gregory Reaman, the Scientific Director of the Childhood Cancer Data Initiative at the National Cancer Institute, on their paper titled “The Childhood Cancer Data Initiative: Using the Power of Data to Learn from and Improve Outcomes for Every Child and Young Adult with Pediatric Cancer.” Dr. Reaman, welcome to our podcast. Dr. Gregory Reaman: Thanks very much, Emily. Appreciate the invitation. Emily Zabor: Dr. Reaman, could you start by introducing yourself and describing your involvement in the Childhood Cancer Data Initiative? Dr. Gregory Reaman: I'm Gregory Reaman. I'm a Pediatric Oncologist. And I guess my involvement with the CCDI began shortly after the initiative was announced at the State of the Union media address in 2019, which was followed shortly thereafter by the formation of a working group by the NCI's National Cancer Advisory Board Board of Scientific Advisors. Given my role at the FDA at that time as Associate Director for Pediatric Oncology in the Oncology Center of Excellence, and the fact that I was the founding Chair of the Children's Oncology Group, I was an ex-officio member of this working group. So from very early on, I had involvement. I formally joined the NCI in November, left the FDA to assume the position as Scientific Director of CCDI. Emily Zabor: That's great. So you've really been involved from the start. I had not really been familiar with the initiative until I read this paper. And as a cancer biostatistician, I was really excited to learn about this initiative, which sounds like it will ultimately create a very valuable data resource to be used for research purposes, among other things. So I think it's a really interesting project. So for our listeners who may not be familiar, could you describe the motivation for and goals of the Childhood Cancer Data Initiative? Dr. Gregory Reaman: As I mentioned, this really is a very unique initiative, venture, if you will, on the part of the Cancer Institute and in large part driven by this fortunate infusion of funds to support childhood cancer research. And given the fact that pediatric oncology is very much a collaborative enterprise, it really does sort of follow that data sharing and using the power of data, its ability to be used by multiple investigators, irrespective of the source, aspirationally can improve outcomes for children cancer. The three primary objectives– actually, this working group that I mentioned earlier put together a white paper that had 24 specific recommendations to the NCI. But there were three foundational objectives or goals. One was to learn from every child diagnosed with cancer, irrespective of the institution where they were diagnosed to receive therapy, to develop an ecosystem that would enable the submission, aggregation of data, and harmonization in a federated system that could then be accessed and used by investigators and analyzed to ultimately improve outcomes. And then one objective, which was a little bit more specific, and that was to really focus on the opportunity to genomically classify tumors from newly diagnosed pediatric cancer patients, because this was something that obviously is much more widespread in the adult population, given the advent of targeted therapy and precision oncology and its more widespread use in medical oncology than pediatrics. And although many large academic institutions do have resources, the majority of smaller institutions do not. And when it's necessary and preferable to accurately and timely identify or diagnose a child's cancer that may actually provide information on treatment recommendations, the ability to do that and have it covered by insurance is sometimes problematic. So developing a program that would not cost patients or institutions anything and then make that data available to patients, families, and providers, as well as making it available for secondary research use, was a major goal and objective. Emily Zabor: Yeah, that sounds like such an important initiative. The Molecular Characterization Initiative, which I understand has already enrolled and characterized the genomics of 751 participants just in the first year, I think is what the paper reported? Dr. Gregory Reaman: That's correct. That was in the first year. We're now beyond the first year and we're approaching 2000 patients that have had their tumors genotyped and about 1500 results that have been returned to patients and providers. Emily Zabor: That's fantastic. So with this linkage to the clinical data, that's going to be an extremely important data source. And I understand that the participation is currently limited to members of the Children's Oncology Group, which consists of over 200 children's hospitals, universities, and cancer centers. Can you describe in more detail what information it currently provides and how this initiative is going to be advertised and implemented to ensure complete participation across all of these member sites? Because that sounds like a really big challenge. Dr. Gregory Reaman: Limiting the participation to the Children's Oncology Group initially was in no way meant to be exclusionary, but really provided an opportunity for linkage to clinical data. Since the Children's Oncology Group really represents nearly all of the pediatric cancer programs in the United States and some programs even outside the US, in Canada, and a couple of European sites, Australia and New Zealand, it was felt that given the resources that currently exist within the COG for specimen procurement, specimen submission, and then DNA and RNA extraction through the COG's Biopathology Center at the Nationwide Children's Hospital would really facilitate having the sequencing done at a single site, single institution, using a single platform. And also it provided an opportunity for some clinical data, including demographics, diagnosis, radiographic data, and treatment data that could be collected somewhat longitudinally from patients enrolled on the MCI. Looking to make this as broad as possible since the objective of the CCDI is to learn from every patient, and every patient that we're concerned about not being able to capture adequately within the Children's Oncology Group are older adolescents and young adults with cancers that are more frequently seen in the pediatric population. So we are looking at ways to work with the COG's Biopathology Center to see if we can create systems that we can actually have specimens submitted from patients seen at institutions outside of the COG and molecularly characterized the same way. And that will be important as we launch another new planned initiative called the Coordinated National Initiative for the Treatment of Rare Pediatric and Young Adult Cancers. Emily Zabor: Okay, that makes sense. So those adolescents and young adults are harder to capture since they're not being seen at those COG member institutions. Okay, well, that sounds like a big challenge to find those patients at their institutions and get them involved, but I think it's an important piece of this for sure. Dr. Gregory Reaman: I should also point out that there were opportunities for some of the larger well, for all of the NCI-designated cancer centers, the pediatric programs associated with those cancer centers, to submit genomic data on newly diagnosed patients. That was something that actually transpired early on in the history of CCDI. So those data are in the CCDI's ecosystem. Emily Zabor: Oh, that's great. So you collected the existing data. Dr. Gregory Reaman: Right.  Emily Zabor: That kind of leads into my next question about aggregating data sources. With these disparate sources of pediatric cancer data, it seems like the aggregation is a lofty and important goal, but once that's complete, you're going to have this data ecosystem, which you said was one of the main goals of this initiative. I was wondering if you could tell us who will have access to this data ecosystem and what will be required for individuals to gain access. Dr. Gregory Reaman: All of CCDI was predicated on this really being a community initiative if you will, so multidisciplinary and community-based. So patients, families, advocates, clinical researchers, physician providers, basic and translational researchers, researchers in public health and epidemiology. So there will be different levels of data that will be available to specific individuals. Patient-level data will be deidentified through a system of APIs that will be used that will enable the association of clinical data to existing molecular data and outcome data that might be available in the ecosystem. Those data will be- there are many data in the ecosystem that will be open source and available to anyone who is interested. This includes data from the NCCR in the Childhood Cancer Data Catalog, which is basically a listing of some close to 300 pediatric cancer databases that are available. The patient-level data will be sort of a controlled access. So there will be a requirement for individuals, investigators who wish to access that data, to sort of be certified, if you will, utilizing NCI and NIH data sharing requirements. Emily Zabor: That makes sense. Yeah, you mentioned deidentification, but especially when we're dealing with these kinds of rare diseases, patient privacy does seem like it could be a concern. So what exactly are you doing to ensure that that is not something that gets violated through this process? Dr. Gregory Reaman: I think there's every attempt to eliminate any PPI, HPI, obviously. So, again, most of the clinical data that are being provided currently are data that's coming from the Children's Oncology Group, where for every patient enrolled or registered through the COG and enrolled on a clinical trial, there is a COG ID number that is associated and that will be available only to the NCI and the CCDI to link it to unique specimen identification numbers, which are the only numbers that will be available to any investigator. So no one will be able to make the connection from the specimen identifier to the unique patient identifier in the COG. Emily Zabor: That's great. And that way, you can really get access to all of the detailed data without concerns about privacy. Dr. Gregory Reaman: Correct. And then being able to link all of these disparate data sets will really require the identification or the development, I should say, of a participant index. So that is one of our highest priorities right now in developing a CCDI participant index so that we would be able to link the identifier or clinical data with any research data or biologic data that may be available on patients to facilitate research plans and programs. Emily Zabor: And through that process, is there also some method involved for identifying duplicated data? Because I assume some of these patients may get seen at different institutions over time, and that could be a concern that they end up in the database multiple times. Dr. Gregory Reaman: That's exactly why I think developing the participant index is so critical to, number one, link, and number two, to avoid, prevent duplication, because you're absolutely right. There may well be the same patient data in multiple data sets, which are, of course, disparate. And the only way that they're going to be really utilizable and made interoperable is by linking them to the specific patient or individual patient. Emily Zabor: Great. And do you have an idea of the timeline when that part would be complete and this data ecosystem would be available to researchers?  Dr. Gregory Reaman: The ecosystem is already available to researchers. We launched several months ago the CCDI hub, which is sort of the entryway or entry point, if you will, for access to the ecosystem. We hope to actually have the participant index up and running, and it's something that we've been working on for over a year, but actually available and utilizable within the next several months.  Emily Zabor: That's fantastic. We'll have to go check out the CCDI hub that's already out there then. Before we end, is there anything you'd like to share with our listeners that we haven't already discussed? Dr. Gregory Reaman: Well, I think the one program that I mentioned just briefly, the Coordinated National Initiative for Rare Pediatric and Young Adult Cancers, we see there's a real opportunity to address a major unmet need. Fortunately, all pediatric cancer is rare, but there are some cancers that are extremely rare and for which there are, in many cases, no defining standard of care, and in many cases, there are no treatment protocols because of the difficulty mounting studies with such small patient numbers. So we see this as an opportunity to actually develop a registry that will provide, hopefully, natural history data that will inform clinical trials. All of these patients will be enrolled on the Molecular Characterization Initiative. So there will be the opportunity to hopefully learn if there are specific molecular drivers of some of these cancers that could inform the use of targeted drugs in a therapeutic approach to some of these. And we're looking to do this international collaboration with colleagues in the EU as well. So that is something that we just launched a task force  to develop a listing of core critical data elements to collect on patients and then developing the registries for a number of these rare cancers. Emily Zabor: That sounds like it's going to be a really valuable resource for planning and designing future clinical trials, so I'm glad to hear about that. Dr. Gregory Reaman: And we would invite anyone who's interested to find out about the CCDI, to find out more about the CCDI, which they can do through cancer.gov/ccdi. There is an opportunity for people to register for newsletters. We have a series of webinars, many of which are designed now to actually provide training on some of the resources and platforms that are available currently through the ecosystem and things that we have all planned for future developments and use. So as I said, this is a community venture and we look to expand the community in every way possible. Emily Zabor: That sounds great. So hopefully our listeners will take note of some of those resources in addition to this paper being out there, which will guide some people in the right direction to learn about this really great initiative for childhood cancer.  So, Dr. Reaman, it has been a pleasure speaking with you. And thank you so much for joining me today on this episode of JCO Article Insights. Dr. Gregory Reaman: Thank you very much. It's been great to be here. Appreciate the opportunity.  Emily Zabor: This concludes this episode on the article, “The Childhood Cancer Data Initiative Using the Power of Data to Learn from and Improve Outcomes for Every Child and Young Adult with Pediatric Cancer.” Thank you all for listening and please tune in for the next issue of JCO Article Insights.  The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experiences, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

This week, we sit down with Alice Rhoton-Vlasak, MD and Lauren Staley, ARNP to discuss fertility preservation in oncology patients.Alice Rhoton-Vlasak, MD, is a board-certified, fellowship-trained reproductive endocrinologist and a professor at the University of Florida Department of Obstetrics and Gynecology working in the division of reproductive endocrinology and infertility. Many of her clinical efforts have focused on fertility and fertility preservation in cancer patients. She started a program called the UF Health HOPE network. This program has three prongs, including research, clinical, and education for all healthcare providers to become familiar with fertility preservation services. Lauren has worked at the University of Florida in the Division of Pediatric Oncology since 2011, serving as the Pediatric Solid Tumor Coordinator. She completed training through the NIH-funded ENRICH (Educating Nurses about Reproductive Issues in Cancer Healthcare) program. In 2019, Lauren joined the UF Health Reproductive Endocrinology group in the role of Oncofertility Navigator. Through this initiative, Lauren provides fertility preservation counseling for patients facing a new cancer diagnosis. 

Today's Life Question of the Week asks, is it “too much” to constantly think of more goals you want to accomplish when you have already been very successful in achieving your current dreams?  Next, Michael welcomes Dr. Joseph Michael Levry, an internationally renowned scholar, composer, author, and speaker, whose universal message brings together the spiritual healing traditions of the East and West. In this interview, they discuss Dr. Levry's dynamic work including a study published in the Journal of Pediatric Oncology and Hematology demonstrating that certain selections from Dr. Levry's Healing Beyond Medicine music series reduced pain in children undergoing cancer treatment; the mystical power of our voice to support healing depression, anxiety, and mental and emotional trauma; how our voice combined with our breath can support us in transforming our thoughts–and a lot more!  Find Dr. Levry on social media and check out his links: https://josephmichaellevry.com/ https://harmonyumhealing.com/ https://shop.rootlight.com/ https://givingnaam.com For practical spiritual insight and encouragement around relationships, finances, health, life purpose, or in understanding world events, submit your Life Question of The Week, to podcast@michaelbeckwith.com.   And remember to subscribe/follow and set an alert to receive notifications each Wednesday when new episodes are available! Connect with Michael at https://michaelbeckwith.com/ and www.Agapelive.com. Facebook: @Michael.B.Beckwith https://www.facebook.com/Michael.B.Beckwith IG: @michaelbbeckwith https://www.instagram.com/michaelbbeckwith/ Twitter:  @drmichaelbb https://twitter.com/drmichaelbb YouTube: https://www.youtube.com/channel/UCqMWuqEKXLY4m60gNDsw61w

Paul A. Northcott, Ph.D., St. Jude Children's Research Hospital, shares his work in multi-omic bulk and single-cell approaches to decipher molecular landscapes and developmental origins of medulloblastoma. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38889]

Paul A. Northcott, Ph.D., St. Jude Children's Research Hospital, shares his work in multi-omic bulk and single-cell approaches to decipher molecular landscapes and developmental origins of medulloblastoma. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38889]

Paul A. Northcott, Ph.D., St. Jude Children's Research Hospital, shares his work in multi-omic bulk and single-cell approaches to decipher molecular landscapes and developmental origins of medulloblastoma. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38889]

Paul A. Northcott, Ph.D., St. Jude Children's Research Hospital, shares his work in multi-omic bulk and single-cell approaches to decipher molecular landscapes and developmental origins of medulloblastoma. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38889]

Paul A. Northcott, Ph.D., St. Jude Children's Research Hospital, shares his work in multi-omic bulk and single-cell approaches to decipher molecular landscapes and developmental origins of medulloblastoma. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38889]

In Episode 11 of World of Wishes, Kelley McCarthy - Pediatric Oncology Nurse and Make-A-Wish Volunteer, talked about how rewarding the Wish Granting experience is for her personally, and how professionally she can truly see the impact that the wishes have on Wish Kids before/after their wish comes true. Learn more about how YOU can refer a child today at https://wish.org/refer-a-child.Kelley is 1 of 500 Make-A-Wish volunteers in our local community, visit https://wish.org/sfla/volunteer to learn more about becoming a volunteer! Be sure to follow us @makeawishsfla on Instagram, Facebook, YouTube, Twitter, TikTok, and LinkedIn!Subscribe, Rate, & Review this podcast to support future episodes that will feature wish kids and parents' past and present, volunteers, donors, referral sources and everyone who contributes to this World of Wishes!

Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Giselle Sholler, Director of the Isabella Santos Rare and Solid Tumor Program at the Levine Children's Hospital, and Professor of Pediatrics and Principle Investigator of the Sholler Pediatric Oncology Research Laboratory. Together they discuss trends in managing pediatric hematologic cancers and how molecular profiling and genomic profiling intersect with clinical care. For more information, please visit: www.CarisLifeSciences.com

Guest: Kristin Szymanek, MA, CCC-SLP - In this episode, Michelle and Erin are joined by Kristin Szymanek, MA, CCC-SLP, Director of Rehabilitation Services at St. Jude Children's Research Hospital in Memphis, Tennessee. The terms “Pediatric Cancer,” “Palliative Care,” and “Hospice” can easily send shivers down your spine. These terms can stir emotions that are intrinsically difficult to grasp. However, as pediatric speech-language pathologists, we may have the joy of working with little ones and their caregivers while they navigate their journey with pediatric cancer or pediatric feeding and/or swallowing disorders, clinical swallow evaluation or instrumental examination, suspected language delay, or even be called upon to evaluate and treat a suspected phonological impairment. Kristin will guide you on the SLP's role and responsibilities as part of an oncology team, including unique barriers when working in this setting and with this population and how to infuse grace and evidence-based practice into palliative care.

In this episode of the FreshRN Podcast, Kati interviews Morgan Melancon MSN, RN, CCRN-K and Annabeth Davis, MSN, RN, NPD-BC. It's Part II of our two-part interview. Morgan is the director of Nursing Education and Professional Development at St. Jude Children's Research Hospital in Memphis, and Annabeth is the manager of Transition to Practice within the department of Nursing Education of the same organization. We discuss: Special training required to give chemotherapy What people love about working oncology and what's particularly challenging End of life care Specific common nursing responsibilities unique to oncology Show notes are located here: https://www.freshrn.com/st-judes-oncology/ If you're interested in learning more about St. Jude's nurse residency program, click here: https://www.stjude.org/jobs/hospital/clinical-careers/nursing/new-nurse-graduates.html Get weekly tips, encouragement, stories from the bedside and more - just for nursing students and new nurses at: https://www.freshrn.com/ Connect With Me Online! Facebook: https://www.facebook.com/FreshRN Twitter: https://twitter.com/Kati_Kleber Pinterest: https://www.pinterest.com/Fresh_RN/ Instagram: https://www.instagram.com/kati_kleber/ TikTok: https://www.tiktok.com/@freshrn 

When it comes to kids and cancer, those two things combine to create a pretty grim picture. But what happens to patients and families after cancer treatment when kids have gone through treatment and survived?  From leukemia being the most common pediatric cancer to the necessary follow up and the psychosocial implications for patients and families, navigating life after a pediatric cancer diagnosis is a complicated process.  Katie Reid is a PA-C who specializes in pediatric cancer survivorship and she's sharing about this dream job and how surprisingly joyful her position is treating these children who have survived from and triumphed over cancer.  EMAIL KATIE katiereid26@gmail.com SPONSORS MASTERING THE MEDICAL INDUSTRY https://1patientatatime.com/waitlist  COACHING 1-ON-1 NEGOTIATION CONSULT https://calendly.com/the-pa-is-in/negotiate  FREE 30-MINUTE COACHING CONSULT https://calendly.com/the-pa-is-in/gen-call   RESOURCES CORE VALUE CURATOR https://tracybingaman.com/values  5 MISTAKES GUIDE https://tracybingaman.com/mistakes  THE PAY PAY ONE SHEET https://tracybingaman.com/one  THE DECISION FRAMEWORK https://tracybingaman.com/decide  THE BURNOUT RISK ASSESSMENT https://tracybingaman.com/burnout-quiz  THE PA PERSONALITY QUIZ https://tracybingaman.com/type  LINKS SHOW NOTES https://www.tracybingaman.com/blog TRACY ON INSTAGRAM https://www.instagram.com/mrstracybingaman/ ON LINKEDIN https://www.linkedin.com/in/tracybingaman/

What is their WHY? Find out when Wendy talks with Stephanie Langevin and Whitney Horsley of CHKD. They share the unique caregiving perspective from pediatric oncology and the gift of grace in helping children and thier families navigate the world of cancer.

After watching her older brother successfully battle Leukemia as a teenager, Jen Costa decided early on that she wanted to be a Pediatric Oncology Nurse. On today's podcast, Jen will talk about her nearly 20 year career that she has spent working with patients suffering from Pediatric Cancer at the Dana Farber Cancer Institute,  as well as many other parts of nursing that she has been adding to her resume. One of Jen's major objectives is to work on a study that involves interviewing both parents of pediatric cancer patients and pediatric oncology nurses.  If anyone is interested in participating in Jen's study, then please contact her at jennifer.costa@umassmed.edu.Jen's website concerning this study is www.parentnurserelationships.wordpress.com 

Season 5 Episode 7- Join me at the mic with Ashley Brooks. She is down to Earth and breaks down her experience as a young survivor. She discusses the ups and downs of her experience and how she is rising above her late effects. For show notes and more, visit:www.livingwithscanxiety.orgSupport the show

Season 4 Episode 4-Pediatic Oncology We are excited to bring you our first podcast with Continuing Education credit for pharmacists and pharmacy technicians! This week we sit down with Dr. Tara Higgins to discuss pediatric oncology. Dr. Higgins serves as assistant professor of pharmacy practice at LECOM School of Pharmacy in Bradenton, FL.  To register for the CE click here:https://www.lecturepanda.com/r/PedsPodCE The objectives of today's podcast are: To identify the differences between adult and pediatric oncologyTo summarize the role of the pharmacist and pharmacy technician in pediatric oncologyTo recognize the challenges when treating pediatric patients with cancer

On episode 402 of The Nurse Keith Show nursing and healthcare career podcast, Keith interviews Cindy Schmus, MSN RN CRNP, a dedicated nurse mentor, educator, and pediatric nurse practitioner. In the course of their conversation, Keith and Cindy discuss the intimacy of pediatric oncology nursing. They also take a deep dive into the magic of mentoring, Cindy's powerful storytelling, and her motto, "I practice what I teach so I can teach what I practice". Cindy Schmus is currently a pediatric nurse practitioner at The Children's Hospital of Philadelphia where she has been an oncology nurse for 35 years. Her specialty is Neuro Oncology and she is an expert if chemotherapy supportive care, managing toxicities and anticipatory guidance for families. She is also associate program director in the Pediatric Acute care Nurse Practitioner Program at the University of Pennsylvania, where she teaches specifically oncology as a concentration for nurses hoping to specialize in their advanced practice. She is a member of the editorial board for PEDIATRIC Nursing and has been a Professional consultant for over 10 years to the Student Nurses Association of Pennsylvania(SNAP). She has been married to John for 30 years and has two thriving, adult daughters both living in Philadelphia. Nurse Keith is a holistic career coach for nurses, professional podcaster, published author, award-winning blogger, inspiring keynote speaker, and successful nurse entrepreneur. Connect with Nurse Keith at NurseKeith.com, and on Twitter, Facebook, LinkedIn, and Instagram. Nurse Keith lives in beautiful Santa Fe, New Mexico with his lovely fiancée, Shada McKenzie, a highly gifted traditional astrologer and reader of the tarot. You can find Shada at The Circle and the Dot. The Nurse Keith Show is a proud member of The Health Podcast Network, one of the largest and fastest-growing collections of authoritative, high-quality podcasts taking on the tough topics in health and care with empathy, expertise, and a commitment to excellence. The podcast is adroitly produced by Rob Johnston of 520R Podcasting, and Mark Capispisan is our stalwart social media manager and newsletter wrangler.

A nurse shares what it was like when her daughter was diagnosed with an aggressive cancer during the beginning of the COVID-19 pandemic. 

Welcome to the series finale of The Cancer Mavericks. In this final episode, we reflect on the first seven episodes through the lens of history and progress with a series of insightful conversations featuring some of healthcare's most influential and visionary voices across the past four decades. If history is a teacher, we have learned that change can happen, albeit slowly. But it is only when the people stand up, organize and activate their voices demanding change, that the culture will shift, the institutions will pivot, and the very system itself will be forced by the will of the citizens to bend towards the arc of justice. Thank you for joining us for this groundbreaking series. If you like this series, please leave a review and a rating on your favorite podcast app. To learn more about The Cancer Mavericks, visit https://CancerMavericks.com. To learn more about OffScrip Health, visit https://OffScrip.com.FEATURED VOICESGil BasheChair Global Health and Purpose, FINN PartnersJohn D. Carpten, Ph.D.President's Cancer Panel (Emeritus)Director, Institute of Translational GenomicsKeck School of Medicine at USCDeanna DarlingtonPresident at Links2EquityKenny KaneYoung Adult Cancer Advocacy PioneerCo-Founder/CEO, Stupid Cancer (Former)Margaret LawsPresident and CEO, Hope LabLisa C. Richardson, MD, MPHDivision Director, Cancer Prevention and Control at The CDCCatharine Young, Ph.D.Assistant Director of Cancer Moonshot Engagement and PolicyThe White HouseSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode Dr's J and Santhosh talk about pediatric cancers with the help of pediatric oncologist Dr Nicole Bakke. Along the way, they cover the earliest described form of cancer, medical etymology, carcinization, metastasis, chimmney sweep soot warts, positive news about treatment rates, the jackalope, solid and liquid tumors, acute leukemias, the father of pediatric oncology, remission definitions, sanctuary testicles, mustard gas and chemotherapy, cancer causing treatments, charitable organizations and more! So sit back and erelax as we cut into the topic of cancer!Further readingSoot wart: https://en.wikipedia.org/wiki/Chimney_sweeps%27_carcinoma#/media/File:Chimney_sweep's_cancer_Wellcome_L0062113.jpgSupport Us spiritually, emotionally or financially here!Twitter: @doctorjcomedy @toshyfroInstagram: @travelmedicinepodcastSpotify: https://open.spotify.com/show/28uQe3cYGrTLhP6X0zyEhTFacebook: facebook.com/travelmedicinepodcastPatreon: https://www.patreon.com/travelmedicinepodcast Supporting us monthly has all sorts of perks! You get ad free episodes, bonus musical parody, behind the scenes conversations not available to regular folks and more!! Your support helps us to pay for more guest interviews, better equipment, and behind the scenes people who know what they are doing! https://plus.acast.com/s/travelmedicinepodcast. Hosted on Acast. See acast.com/privacy for more information.

We all know the cliché that laughter is the best medicine. In addition to laughter, research suggests that levity and empathy are also great medicines. One of the best testing grounds I can imagine for considering the value of levity and empathy would have to be the pediatric oncology department. For the children and for the parents, the challenges faced there can be simply overwhelming. What's it like to work in the pediatric oncology department? What skills are most useful in helping the children and parents who are facing some of the heaviest burdens imaginable? And how might bringing empathy and levity be a part of serving those patients and parents as they deal with these burdens? As it happens, I know just the guy to ask! Marc Bader is a registered nurse who works in a pediatric oncology department in Silicon Valley. As you will hear, Marc is the embodiment of kindness, compassion, the desire to help, and one of the finest transmitters of levity I have ever known. He will share with you his method for helping people in their darkest hours. And, I expect you will glean from Marc various ways you can rock these skills in your personal and professional lives when you want to assist people who are in difficult places. So, listen in as Marc and I talk about bringing levity and empathy to serious situations.

Dr. Lisa Diller has had many titles during her great career at Dana Farber and Boston Children's Hospital. These titles include being the Chief Medical Officer at Dana Farber, the Vice Chair of Pediatric Oncology at Dana Farber,  and the Director of the David Perini Quality of Life Clinic for Pediatric Cancer Survivors. On today's Podcast Dr. Diller will talk about the difficulty of Neuroblastoma, the subject of Genetic Testing for very young children, and Long Term Survivorship for pediatric cancer patients who have recovered from their cancer battles and now have to focus on how to  prosper as they move on with their lives. 

In today's show, Pancham interviews Drew White - upside down wealth consultant for business owners & executives. Former pediatric oncology nurse with a $150,000 student loan debt, Drew realized that nursing is not a long-term gig for him. He came across infinite banking while learning about money and distinguishing between bad and good debt. With his “aha!” moment, he is now on a path to entrepreneurship real estate investing, infinite banking, and teaching others how to do the same! Be the banker yourself as he teaches the concept of infinite banking and how you can get the same rewards that the bank does. Learn from his journey as he shares his principles, why you should utilize the whole life insurance policy, and other added benefits that you can get! Listen and enjoy the show!   Quote: “I started reading what other people did and that's when I realized, ‘Oh okay, a lot of people are doing real estate. A lot of smart wealthy people have been doing real estate for a long time.' ” Timestamped Shownotes: 0:36 - Pancham introduces Drew to the show 2:21 - From $150,000 student loan debt to using debt to build wealth 9:50 - Infinite banking and enjoying the rewards the bank receives 12:16 - How a whole life insurance policy helps in obtaining the bank's benefits 19:22 - Creditor protection and using other perks for real estate investing 22:12 - On attaining the policy and transferring its ownership to his children 27:21 - Things to consider when setting up with a mutual insurance company 30:23 - Taking the Leap Round 30:23 - His 1st mobile home investment outside of Wall Street 31:10 - Overcoming his fear of imperfection when he first started 33:15 - How lack of due diligence led to an unsatisfactory investment 34:31 - Pieces of advice to rookie investors to get their journey started 35:51 - How you can connect with Drew 3 Key Points: The idea of infinite banking is to keep money in your own system rather than in a bank. In this way, you would get the benefits that the bank originally receives. Although a whole life insurance policy may appear to be a poor investment, it is beneficial when it is viewed as your own bank account. Work with someone who has experience and is willing to coach you. Working with mentors will be highly advantageous as you scale up your business. Get in Touch: Drew White Website - https://www.ibcdrew.com/ CreateTailwind Website - https://createtailwind.com/ Drew White LinkedIn - https://www.linkedin.com/in/ibcdrew/ The Gold Collar Investor Club - https://thegoldcollarinvestor.com/club/ Pancham Gupta Email - p@thegoldcollarinvestor.com Book: Becoming Your Own Banker by R. Nelson Nash - https://www.amazon.com/Becoming-Your-Banker-Nelson-Nash-ebook/dp/B0080K8EL4

Today's episode is underwritten by Aflac, a proud supporter of Charting Pediatrics and Children's Hospital Colorado. For more than 20 years, Aflac has dedicated its heart and philanthropic mission to helping children with cancer. Thank you to Aflac for envisioning a world without pediatric cancer by supporting our Center for Cancer and Blood Disorders. Please visit our Charting Pediatrics website to learn more about becoming an underwriting sponsor. Pediatric cancer is a devastating diagnosis that thousands of patients and families receive a year. When faced with such a diagnosis, it is crucial that patients and families have access to the most current and effective treatment options as possible.  In the past few decades, pediatric cancer survival rates have improved immensely. Today, we are going to be discussing the treatment options, clinical trials, and the disparities and equity in pediatric oncology. Today, I am happy to be speaking with my collogues Dr. Adam Green and Dr. Kelly Faulk. Both Dr. Green and Dr. Faulk are a part of the Center for Cancer and Blood Disorders Team at Children's Hospital Colorado. Dr. Green specializes in Pediatric Oncology and is an Associate Professor of Pediatrics at the University of Colorado School of Medicine. Dr. Faulk is also an Assistant Professor of Pediatrics and specialize in pediatric Leukemia and Lymphoma, with research focused on early phase trial design and experimental therapeutics for high risk forms of leukemia.